330350 — Withus Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩108bn
- KR₩118bn
- KR₩80bn
- 70
- 59
- 21
- 48
2019 June 30th | 2020 June 30th | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 28,624 | 44,674 | 42,478 | 26,556 | 11,192 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20,988 | 21,844 | 24,228 | 23,372 | 30,978 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 55,132 | 73,530 | 76,427 | 59,451 | 58,247 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 12,319 | 19,383 | 25,379 | 39,843 | 49,945 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 76,283 | 107,013 | 118,979 | 119,395 | 130,780 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 18,167 | 24,161 | 23,975 | 25,572 | 31,011 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 23,854 | 30,253 | 38,074 | 36,359 | 40,502 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 52,429 | 76,759 | 80,905 | 83,036 | 90,278 |
Total Liabilities & Shareholders' Equity | 76,283 | 107,013 | 118,979 | 119,395 | 130,780 |
Total Common Shares Outstanding |